Litcius/Paper detail

Asymmetric Cation‐Olefin Monocyclization by Engineered Squalene–Hopene Cyclases

Michael Eichenberger, Sean Hüppi, David Patsch, Natalie Aeberli, Raphael Berweger, Sandro Dossenbach, Eric Eichhorn, Felix Flachsmann, Lucas Hortencio, Francis Voirol, Sabine Vollenweider, Uwe T. Bornscheuer, Rebecca Buller

2021Angewandte Chemie International Edition23 citationsDOIOpen Access PDF

Abstract

Squalene-hopene cyclases (SHCs) have great potential for the industrial synthesis of enantiopure cyclic terpenoids. A limitation of SHC catalysis has been the enzymes' strict (S)-enantioselectivity at the stereocenter formed after the first cyclization step. To gain enantio-complementary access to valuable monocyclic terpenoids, an SHC-wild-type library including 18 novel homologs was set up. A previously not described SHC (AciSHC) was found to synthesize small amounts of monocyclic (R)-γ-dihydroionone from (E/Z)-geranylacetone. Using enzyme and process optimization, the conversion to the desired product was increased to 79 %. Notably, analyzed AciSHC variants could finely differentiate between the geometric geranylacetone isomers: While the (Z)-isomer yielded the desired monocyclic (R)-γ-dihydroionone (>99 % ee), the (E)-isomer was converted to the (S,S)-bicyclic ether (>95 % ee). Applying the knowledge gained from the observed stereodivergent and enantioselective transformations to an additional SHC-substrate pair, access to the complementary (S)-γ-dihydroionone (>99.9 % ee) could be obtained.

Topics & Concepts

Enantiopure drugSqualeneEnantioselective synthesisStereochemistryChemistryStereocenterBiocatalysisTerpenoidOlefin fiberCatalysisOrganic chemistryReaction mechanismPlant biochemistry and biosynthesisPharmacological Effects of Natural CompoundsNatural product bioactivities and synthesis
Asymmetric Cation‐Olefin Monocyclization by Engineered Squalene–Hopene Cyclases | Litcius